As different pathways regulated by PERK and HSPA5 contribute to both cancer progression and therapy resistance, attempts to target PERK and/or HSPA5 individually, jointly, or with other potential targets can yield higher efficacy, particularly in cancers overexpressing HSPA5 or PERK. Here, EIF2AK3 is linked to cancer.